Are Analysts Bullish Impax Laboratories, Inc. (NASDAQ:IPXL) After Last Week?

December 11, 2017 - By Winifred Garcia

 Are Analysts Bullish Impax Laboratories, Inc. (NASDAQ:IPXL) After Last Week?
Investors sentiment decreased to 0.9 in 2017 Q2. Its down 0.40, from 1.3 in 2017Q1. It is negative, as 28 investors sold Impax Laboratories, Inc. shares while 53 reduced holdings. 24 funds opened positions while 49 raised stakes. 62.83 million shares or 2.46% more from 61.32 million shares in 2017Q1 were reported.
Tcw Grp Incorporated invested in 37,580 shares or 0.01% of the stock. Invesco Limited holds 718,225 shares or 0% of its portfolio. Sg Americas Securities Ltd Liability Corporation has 0.01% invested in Impax Laboratories, Inc. (NASDAQ:IPXL). Bridger Management owns 1.23% invested in Impax Laboratories, Inc. (NASDAQ:IPXL) for 1.34M shares. Lsv Asset Mgmt has invested 0% of its portfolio in Impax Laboratories, Inc. (NASDAQ:IPXL). Principal Fincl Group reported 562,743 shares. Zurcher Kantonalbank (Zurich Cantonalbank) has 3,175 shares. Bankshares Of America Corporation De stated it has 0% of its portfolio in Impax Laboratories, Inc. (NASDAQ:IPXL). Thrivent For Lutherans holds 0% or 44,630 shares. Envestnet Asset Mgmt accumulated 0% or 2,759 shares. Bancorporation Of Montreal Can holds 0% of its portfolio in Impax Laboratories, Inc. (NASDAQ:IPXL) for 54,383 shares. Northern Tru accumulated 943,704 shares. Citadel Advsrs Limited Com, a Illinois-based fund reported 2.18 million shares. Stifel Fin Corporation accumulated 636,863 shares or 0.04% of the stock. Dekabank Deutsche Girozentrale holds 13,100 shares or 0% of its portfolio.

Impax Laboratories, Inc. (NASDAQ:IPXL) Ratings Coverage

Among 20 analysts covering Impax Laboratories Inc. (NASDAQ:IPXL), 5 have Buy rating, 2 Sell and 13 Hold. Therefore 25% are positive. Impax Laboratories Inc. has $60 highest and $1500 lowest target. $26.50’s average target is 57.27% above currents $16.85 stock price. Impax Laboratories Inc. had 45 analyst reports since July 21, 2015 according to SRatingsIntel. RBC Capital Markets maintained Impax Laboratories, Inc. (NASDAQ:IPXL) on Thursday, November 10 with “Sector Perform” rating. On Tuesday, July 18 the stock rating was upgraded by PiperJaffray to “Neutral”. The company was maintained on Friday, September 29 by BMO Capital Markets. RBC Capital Markets maintained the shares of IPXL in report on Tuesday, October 17 with “Hold” rating. As per Friday, July 14, the company rating was maintained by RBC Capital Markets. The company was upgraded on Monday, August 15 by Northland Capital. RBC Capital Markets maintained Impax Laboratories, Inc. (NASDAQ:IPXL) rating on Thursday, August 10. RBC Capital Markets has “Hold” rating and $1700 target. BMO Capital Markets maintained the shares of IPXL in report on Friday, June 23 with “Hold” rating. On Monday, November 7 the stock rating was downgraded by Bank of America to “Underperform”. The stock has “Buy” rating by Cantor Fitzgerald on Tuesday, July 18. Below is a list of Impax Laboratories, Inc. (NASDAQ:IPXL) latest ratings and price target changes.

10/11/2017 Broker: Cowen & Co Rating: Hold New Target: $16.0 Maintain
09/11/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $35.0 Maintain
30/10/2017 Broker: BMO Capital Markets Rating: Hold New Target: $18.0 Maintain
30/10/2017 Broker: UBS Rating: Sell Old Target: $12 New Target: $16 Maintain
17/10/2017 Broker: RBC Capital Markets Rating: Hold New Target: $17.0 Maintain
29/09/2017 Broker: BMO Capital Markets Rating: Hold New Target: $18.0 Maintain
28/09/2017 Broker: Goldman Sachs Rating: Neutral New Target: $20 Initiates Coverage On
15/09/2017 Broker: Piper Jaffray Rating: Hold New Target: $17.0 Maintain
14/09/2017 Broker: RBC Capital Markets Rating: Hold New Target: $17.0 Maintain
13/09/2017 Broker: Canaccord Genuity Rating: Hold New Target: $19.0 Maintain

The stock decreased 0.88% or $0.15 during the last trading session, reaching $16.85. About 169,837 shares traded. Impax Laboratories, Inc. (NASDAQ:IPXL) has declined 49.01% since December 11, 2016 and is downtrending. It has underperformed by 65.71% the S&P500.

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, makes, and markets bioequivalent pharmaceutical products. The company has market cap of $1.25 billion. It operates in two divisions, Impax Generics and Impax Specialty Pharma. It currently has negative earnings. The Impax Generics segment provides generic pharmaceutical products directly to wholesalers, retail drug chains, and others; generic prescription products through third-party pharmaceutical entities pursuant to alliance agreements; generic pharmaceutical over-the-counter and prescription products to third parties; and generic pharmaceutical OTC products through third-party pharmaceutical companies pursuant to alliance agreements.

More important recent Impax Laboratories, Inc. (NASDAQ:IPXL) news were published by: Businesswire.com which released: “SHAREHOLDER ALERT: Rigrodsky & Long, PA Announces Investigation of Impax …” on November 27, 2017, also Prnewswire.com published article titled: “Technical Snapshots for These Drug Makers Stocks — AstraZeneca, Impax …”, Reuters.com published: “BRIEF-Impax Laboratories says co entered into amendment no. 1 to business …” on November 21, 2017. More interesting news about Impax Laboratories, Inc. (NASDAQ:IPXL) was released by: Businesswire.com and their article: “INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale …” with publication date: December 08, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.